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Objectives: This study assesses the power of the BODE index, a multidimensional grading
system that predicts mortality, to predict subsequent exacerbations in patients with COPD.
Design: Prospective cohort study.
Patients and interventions: A total of 275 COPD patients were followed every 6 months up to 8
years (median of 5.1 years). Baseline clinical variables were recorded and the BODE index was
calculated. We investigated the prognostic value of BODE quartiles (scores 0e2, 3e4, 5e6 and
7e10) for both the number and severity of exacerbations requiring ambulatory treatment,
emergency room visit, or hospitalization.
Results: The annual rate of COPD exacerbations was 1.95 (95% CI, 0.90e2.1). The mean time to
a first exacerbation was inversely proportional to the worsening of the BODE quartiles (7.9 yrs,
5.7 yrs, 3.4 yrs and 1.3 yrs for BODE scores of 0e2, 3e4, 5e6 and 7e10, respectively). Similarly,
the mean time to a first COPD emergency room visit was 6.7 yrs, 3.6 yrs, 2.0 yrs and 0.8 yrs for
BODE quartiles (all p< 0.05). Using ROC curves, the BODE index was a better predictor of exac-
erbation than the FEV1 alone (p< 0.01).
Conclusions: The BODE index is a better predictor of the number and severity of exacerbations
in COPD than FEV1 alone.
ª 2008 Elsevier Ltd. All rights reserved.765500; fax:þ34 976566 234.
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Chronic obstructive pulmonary disease (COPD) will become
the third most common cause of death and the fourth cause.
374 J.M. Marin et al.of disability in the world by the year 2020.1 As COPD
progresses, patients develop more frequent and severe
exacerbations,2,3 and have an increased rate of emergency
room visits and hospitalizations.2,4
Hospitalizations for COPD exacerbations account for most
of the economic burden of the disease.5e9 Recurrent exac-
erbations are associated with worsening of lung func-
tion4,10,11 and of health-related quality of life (HRQoL),12 and
with decreased survival.13e15 The mechanisms underlying
COPD exacerbations are poorly understood, and it is a high
priority to identify factors that help predict their occur-
rence.16 Few factors have been associated with the predic-
tion of exacerbations. These include a history of prior
hospitalizations for COPD, a lower FEV1, and more severe
respiratory symptoms.9,17 These descriptors however were
obtained from studies that defined exacerbations using only
short-termchanges in symptoms, did not describe the type of
medical intervention needed,9 or only included patients with
severe disease that required admissions to the hospital.13,17
The BODE index is a multidimensional index of disease
severity in COPD that incorporates four factors known to be
independent predictors of survival in this disease: the body
mass index (BMI), the degree of airflow obstruction
assessed by the FEV1, the functional dyspnea assessed by
the modified Medical Research Council (mMRC) question-
naire, and the exercise capacity assessed by the 6 min
walking distance (6MWD) test. The BODE index proved to be
a good predictor of survival in a large cohort of patients
with COPD.18 It also predicts hospitalizations19 and has
been shown to comprehensively reflect the detrimental
changes occurring during exacerbations.20 Considering that
exacerbations are related to poor clinical outcomes such as
mortality and health status, we hypothesized that the BODE
index could also be a good predictor of future exacerba-
tions assessed with different definitions. Accordingly, we
conducted this study to assess the value of the BODE index
as a predictor of both the number and the severity of COPD
exacerbations.
Methods
Patients
Subjects with a diagnosis of COPD were recruited between
January 1997 and June 2002 at the outpatient pulmonary
clinics of two tertiary teaching hospitals in Tenerife and
Zaragoza, both in Spain. The study group was part of
a larger study examining the value of the BODE index as
predictor of survival in COPD.18 Inclusion criteria were 1)
a history of smoking >20 pack-year, 2) a maximal ratio of
FEV1/FVC< 0.7 measured 20 min after the administration
of inhaled salbutamol and, 3) a stable clinical condition
for at least 8 weeks prior to enrolment. Exclusion criteria
were 1) uncontrolled co-morbidities likely to result in
death, 2) a history of asthma or an increase in the FEV1
greater than 15% or more than 200 ml from baseline after
the administration of inhaled salbutamol and 3) the
inability to perform the required tests. The study was
approved by the human-research review board at each
institution, and written informed consent was obtained
from all patients.Measurements
Forced spirometry was performed according to the guide-
lines of the American Thoracic Society.21 The best of two
6MWD tests was performed as described elsewhere.22,23
Functional dyspnea was assessed using the mMRC dyspnea
scale.24 To quantify the degree of co-morbidity we used the
Charlson index.25 The BODE index was computed as previ-
ously reported.18
Follow-up
Patients included in the cohort attended the clinics every
six months or until death, and a history of exacerbations of
COPD was obtained at each clinic visit. Exacerbations were
defined as events characterized by a sustained worsening of
baseline respiratory symptoms that lasted for at least 3
days and that required treatment intervention with anti-
biotics, and/or systemic corticosteroids. The severity of the
exacerbation was estimated according to the level of
health-care resources utilized (sequentially a non-sched-
uled visit to their primary care physician, assessment at the
emergency room, or hospitalization). These episodes were
confirmed by reviewing the medical and the hospital
records.
Statistical analysis
Data are expressed as means with 95% confidence intervals
or medians for normally and non-normally distributed
variables, respectively. Rates per year of the three
different types of exacerbations were calculated as the
number of hospitalizations, emergency room, and ambula-
tory exacerbations due to COPD divided by the time of
follow-up. We used a KaplaneMeier analysis to determine
time to exacerbations. The correlation between the BODE
index and exacerbation rates was explored using the Rho
Spearman coefficient. The change of variables with time
was measured with a Cox proportional hazard regression.26
The area under the receivereoperator curve (ROC) and an
odds ratio were used as measures for the diagnostic validity
of the BODE index to predict exacerbations.27 The Youden
index, defined as sensitivityþ specificity 1, is also
reported. Their respective confidence intervals are
computed with asymptotic or bootstrap distributions.
Individual slopes of decline of FEV1 and FVC were pooled
according to BODE index and compared by means of the U
of ManneWhitney test. A p value of less than 0.05 was
considered for statistical significance.Results
A total of 275 COPD patients were followed up to 8 years
(median of 5.1 years). Mean age was 65 years. Character-
istics of the patients at entry by study centre are shown in
Table 1. Patients from the Tenerife site had less pack-years
of smoking, a lower dyspnea score, greater exercise
capacity, more use of inhaled corticosteroids and long-
acting bronchodilators, and more COPD exacerbations in
the previous year than patients from the Zaragoza site. All
Table 1 Baseline demographic and clinical characteristics, by centre site.
Zaragoza
(nZ 136)
Tenerife
(nZ 139)
p Value
Age, yr 65.85 7.36 64.31 9.02 0.121
BMI, kg/m2 27.64 27.33 27.03 4.55 0.276
Pack-years 56.23 25.37 48.51 21.76 0.007
FEV1, liters 1.38 0.56 1.24 0.48 0.037
FEV1, % 49.57 17.60 48.47 19.16 0.621
FEV1/FVC, % 45.92 12.16 46.40 12.32 0.748
GOLD 1 (%) 6 (4.4%) 8 (5.8%)
GOLD 2 (%) 57 (41.9%) 50 (36%)
GOLD 3 (%) 42 (30.9%) 42 (30.2%)
GOLD 4 (%) 31 (22.8%) 39 (28.1%)
MMRC dyspnea scale 1.73 1.09 1.29 1.25 0.002
6MWT, meters 449 92 478 87 0.009
BODE index score 2.59 2.08 2.42 1.99 0.488
CHARLSON index 2.74 1.39 2.53 1.32 0.200
Chronic hyper-secretion, % 19.9 15.2 0.315
Previous ICS use, % 55.9 71.7 0.008
Previous LABA use, % 57.4 86.3 0.000
Previous home oxygen, % 9.6 13.8 0.348
Exacerbations of COPD in
the previous year
1.11 1.45 2.21 2.75 0.000
COPD exacerbations and BODE 375other variables were equally distributed in both centres,
with a similar BODE and co-morbidity indices at baseline,
and all were treated according to the same treatment and
management protocols.
Two hundred and forty of the 275 patients included in
the cohort (87.3%) experienced at least one exacerbation
over the study period. The mean annual rate of exacerba-
tions was 1.95 per year. No individuals with BODE 0 required
hospitalization because of an exacerbation of COPD,
whereas all individuals with BODE 8 and above experienced
COPD exacerbations that required hospitalization.
As quantified by different estimators of validity (Table
2), the BODE index was able to predict well all three types
of COPD exacerbations explored in this study. The corre-
lation between the rate of exacerbation with the BODE
index was the best for total COPD exacerbations (Rho of
SpearmanZ 0.720) and for those requiring primary care
only, with all likelihood due to their wider range of values
than for more severe COPD exacerbations. For all other
estimators, COPD exacerbations requiring hospitalizationTable 2 Association of exacerbation definitions with the BODE
Coefficient Total Primary c
Rho of Spearman 0.720 0.661
AUCa 0.81 (0.75e0.87) 0.78 (0.7
Odds ratioa 2.56 (1.77e3.70) 2.09 (1.5
Threshold of BODEb 1.9 (0.9e2.1) 1.9 (0.9e
Sensitivitya 0.71 (0.68e0.73) 0.71 (0.6
Specificitya 0.77 (0.75e0.79) 0.71 (0.6
Youden indexb 0.48 (0.40e0.64) 0.43 (0.3
ER: emergency room.
a 95% Asymptotic confidence interval.
b 95% Bootstrap confidence interval.had the best area under the ROC, odds ratio, highest
threshold of BODE, and best Youden index (Table 2). The
area under the ROC of the BODE index to predict COPD
hospitalizations was 0.88 (Fig. 1, panel A) and emergency
room visits (Fig. 1, panel B) was 0.78 and both were
significantly better than FEV1 alone (p< 0.005). The risk of
having a COPD exacerbation increased with BODE, with the
larger relative risk being seen with COPD hospitalizations
(RRZ 2.51). Similarly, for a given COPD individual, the
BODE threshold to observe a COPD exacerbation requiring
ambulatory care was 1.9, while the BODE threshold for
observing a COPD exacerbation requiring emergency care or
hospitalization was 2.9.
Fig. 2 presents the time to an exacerbation requiring
hospitalization (panel A) or an emergency room visit (panel
B) according to BODE quartiles. Most patients with the
lowest BODE quartile (0, 1 or 2) experienced no hospitali-
zations. Increasing BODE quartiles were associated with the
occurrence of exacerbations requiring hospitalization (p
value <0.01 for all comparisons). Of interest, all COPDindex.
are ER Hospitalizations
0.585 0.608
1e0.85) 0.78 (0.73e0.84) 0.88 (0.83e0.92)
7e2.79) 2.09 (1.68e2.60) 2.51 (1.99e3.17)
2.1) 2.9 (1.9e3.1) 2.9 (2.9e4.1)
8e0.73) 0.58 (0.55e0.61) 0.86 (0.84e0.87)
8e0.73) 0.87 (0.86e0.88) 0.73 (0.71e0.75)
3e0.55) 0.45 (0.36e0.54) 0.59 (0.49e0.68)
Figure 1 Receivereoperator curves for increasing BODE index (continuous line) and decreasing FEV1 (dotted line) as predictors of
an exacerbation before one year: (A) hospitalization and (B) emergency room visit.
376 J.M. Marin et al.patients with BODE higher than 7 had an exacerbation that
required hospitalization before 4 years. The mean time to
a first COPD hospitalization was 7.9 yrs, 5.7 yrs, 3.4 yrs and
1.3 yrs for BODE quartiles of 0e2, 3e4, 5e6 and 7e10,
respectively. A similar trend was observed for exacerba-
tions requiring an emergency room visit (Fig. 2, panel B).
The mean time to a first COPD emergency room visit was 6.7
yrs, 3.6 yrs, 2.0 yrs and 0.8 yrs for the same BODE thresh-
olds. For comparison, in Fig. 3 the same KaplaneMeier
curves are presented by thresholds of FEV1. It can be shown
that curves spread out more for BODE than for FEV1,
especially within the milder COPD subgroups, and differ-
entiate time to a COPD exacerbation earlier with BODE than
with FEV1 alone (p< 0.05).
Discussion
This study shows that the BODE index is a good predictor of
both the number and severity of exacerbations in patients
with COPD. In addition, it predicts COPD hospitalizations
better than less severe COPD exacerbations, namely those
that required primary care or emergency room visit only.
Exacerbations of COPD contribute to accelerated lung
function decline,4,10,11 decreased HRQoL,12 mortality,13,14
and the high socio-economic burden of the disease.5e9Figure 2 Time to exacerbation by BODE quartile: (Preventing exacerbations of COPD, and in particular
hospitalizations, is therefore a major goal in the manage-
ment of patients with this condition. A better under-
standing of the predictors of exacerbations and of
hospitalizations becomes essential for effective imple-
mentation of preventive interventions.16 Our results show
that the BODE index may help achieve this goal. To date
only a few studies have attempted to tease out the factors
that may help predict exacerbations. In the East London
Cohort study, patients who experienced a high frequency of
exacerbations in one year were likely to have more
episodes during the following year.12 This observation has
been confirmed in clinical trials, which also demonstrated
that ‘‘frequent exacerbators’’ exhibited the worse baseline
FEV1.
4 However, the predictive value of FEV1 was mostly
observed at values lower than 50%.28,29 In these studies,
patients with lower scores in HRQoL questionnaires were
also noted to have more frequent exacerbations.12
Regrettably, several important clinical variables such as
exercise capacity, functional dyspnea or nutritional status
were not evaluated in those studies. In addition, the
observations were made in patients with relatively mild
exacerbations attending outpatient clinics, and the defini-
tion used relied only in the change of symptoms as regis-
tered in daily cards in the East London Cohort reports, andA) hospitalization and (B) emergency room visit.
Figure 3 TimetoexacerbationbyFEV1 (%predicted)asper theATS-ERSseverity staging: (A)hospitalizationand(B)emergencyroomvisit.
COPD exacerbations and BODE 377in other operational definitions used in the interventional
trials. To date, only one study has evaluated the factors
associated with admissions for COPD.17 In this study,
a history of prior hospitalizations, a lower FEV1, and under
prescription of oxygen therapy were associated with
a higher risk for admission to the hospital as the result of
a COPD exacerbation. Again, no data on variables such as
functional dyspnea or exercise capacity were collected.
Consistent with our results, however, Ong et al. recently
reported in 127 COPD patients followed up for a mean of 16
months that the BODE index helped to better predict
hospitalizations for COPD than FEV1 alone.
19 However, in
that study no attempt was made to categorize the value of
BODE as predictor of the severity of COPD exacerbation. In
our cohort, a lower FEV1 was associated with both the
exacerbation rate and the risk for hospitalization (albeit
with a lower statistical power compared to the BODE
index). This is at variance with previous studies, where no
relationship between baseline FEV1 and exacerbation
frequency was observed.4,12 Further, in the East London
Cohort study, daily cough and sputum were predictive
factors of exacerbations, whereas in our series and in those
of large clinical trials,28,30 hyper-secretion did not correlate
with an increased risk for exacerbations. These differences
are likely related to the different definitions of COPD
exacerbation used. In the East London Cohort study for
example, a respiratory symptom-based definition was used,
different to the health-care utilization-based definition
used by our group and others. Such interventions include
either a treatment with oral steroids or antibiotics, emer-
gency room visit and/or hospitalization.
We observed that the integration of relatively simple
clinical variables into the BODE index offered the best
predictive value in the univariate and multivariate analysis.
This suggests that a relatively simple integration of variables
obtainable in any medical setting can help select patients
likely to develop more frequent exacerbations. Given that
COPD causes more deaths each year than both lung cancer
and sepsis,1 and that exacerbations are the single most
important event driving both mortality and the cost of care
for COPD patients, the use of BODE appears to be justified.
There are several limitations in our study. First, since
few women were included, we cannot generalize the
results to both genders. Second, our patients were
recruited from those attending specialty clinics andtherefore may not represent the COPD population at large,
especially those with less severe disease. However, the
patients included in our cohort likely represent the ones
that are more likely to experience exacerbations. Third,
and finally, the operational definition of exacerbation was
purely health-care utilization-based, that is, it required
a specific medical intervention. This definition has the
advantage of being based in objective criteria so it is easily
recognized, can be registered accurately, and is well suited
as an outcome in clinical trials31e35; the drawback is that it
may vary between countries or it may depend on local
availability of health-care services. However, consistent
with the observations by Ong et al.19 and Cote et al.20 our
findings appear reasonably generalizable. It is unlikely that
our results are subject to recall bias, as number and
severity of COPD exacerbations were recorded and scored
both from the hospital and primary care medical records of
each patient.
In summary, we have shown that apart from being
a predictor of mortality, the BODE index is also a good
predictor of the number and severity of exacerbations in
patients with COPD. The power to predict exacerbations
is superior to that of FEV1 alone, probably reflecting that
BODE can assess more accurately the pulmonary and the
systemic consequences of COPD.
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